DiscoveryProbe™ FDA-approved Drug Library: High-Throughput Screening for Drug Repositioning and Target Identification

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) is a ready-to-screen collection of 2,320 regulatory-approved bioactive compounds, available as 10 mM DMSO solutions with up to 24 months stability at -80°C. This library supports high-throughput and high-content screening (HTS, HCS) for drug repositioning and pharmacological target identification across oncology, neurodegenerative, and infectious disease research. Representative compounds include doxorubicin, metformin, and atorvastatin, each validated by clinical use and mechanistic annotation. The collection's design allows for integration into automated workflows, with flexible formats such as 96-well plates and 2D barcoded storage tubes. APExBIO provides this resource with extensive documentation and global regulatory coverage (DiscoveryProbe™ FDA-approved Drug Library).

Biological Rationale

The complexity of human disease mechanisms necessitates efficient, broad-spectrum compound screening. Libraries composed of FDA- and internationally approved drugs accelerate preclinical research by leveraging compounds with known safety profiles and pharmacokinetics (Mechanism-Driven Drug Discovery: Strategic Opportunities ...). The DiscoveryProbe™ FDA-approved Drug Library is specifically curated for translational research, enabling rapid assessment of therapeutic potential in new indications (drug repositioning). Using clinically annotated compounds circumvents much of the early-stage toxicity and bioavailability uncertainty, streamlining the identification of modifiable signaling pathways and enzyme targets. This approach is particularly valuable for complex diseases such as cancer and neurodegenerative disorders, where polypharmacology and novel target discovery are critical (Redefining Translational Drug Discovery: Mechanistic Insi...).

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The library encompasses a wide array of mechanistic classes:

• Receptor agonists and antagonists: Includes drugs targeting GPCRs, nuclear receptors, and tyrosine kinase receptors, e.g., beta-blockers and tamoxifen.
• Enzyme inhibitors: Contains kinase inhibitors, protease inhibitors, and histone deacetylase inhibitors; for example, vorinostat and doxorubicin.
• Ion channel modulators: Features calcium channel blockers and sodium channel inhibitors, such as nifedipine and carbamazepine.
• Signal pathway regulators: Compounds modulating Wnt, Notch, and MAPK pathways, supporting pathway-specific screening.

This mechanistic diversity enables hypothesis-driven and unbiased screening for target validation and pathway mapping, as well as phenotypic screens in disease models (DiscoveryProbe™ FDA-approved Drug Library: Verifiable Ben...).

Evidence & Benchmarks

• Comprises 2,320 clinically approved compounds, each with documented mechanism and regulatory provenance (APExBIO).
• Compounds provided as pre-dissolved 10 mM solutions in DMSO, ready for HTS/HCS workflows (DiscoveryProbe™ FDA-approved Drug Library: Verifiable Ben...).
• Stable for 12 months at -20°C and up to 24 months at -80°C, ensuring reproducibility and compound integrity (APExBIO).
• Demonstrated utility in identifying small-molecule inhibitors of hepatitis delta virus ribozyme via cell-based high-throughput screening—four active compounds were identified from 6,644 tested, including 8-azaguanine (Tseligka et al., 2023, https://doi.org/10.1016/j.jhepr.2022.100652).
• Supports workflows in oncology, neurodegeneration, infectious disease, and metabolic disorder research, as documented in recent translational studies (DiscoveryProbe FDA-approved Drug Library: Accelerating Ta...).

Applications, Limits & Misconceptions

The DiscoveryProbe™ FDA-approved Drug Library is optimized for multiple research domains:

• Drug repositioning screening: Identification of new indications for existing drugs.
• Pharmacological target identification: Rapid functional screening in cellular and biochemical assays.
• Cancer research drug screening: Discovery of cytotoxic and pathway-modulating compounds.
• Neurodegenerative disease drug discovery: Screening for neuroprotective or disease-modifying agents.
• Enzyme inhibitor screening: Direct measurement of target engagement for proteases, kinases, and other enzymes.

However, some limitations must be noted. The library does not cover investigational or preclinical-only compounds, so it is not suitable for discovery of entirely novel chemical scaffolds. Compound concentrations are fixed at 10 mM in DMSO, requiring further dilution for in vitro or in vivo work. The collection is not intended for direct clinical use.

Common Pitfalls or Misconceptions

• Not for clinical administration: The compounds are for research use only and are not GMP-grade.
• No guarantee of activity in all models: Activity is context-dependent; negative results do not invalidate compound efficacy in other systems.
• Limited to approved drugs: Excludes investigational new chemical entities and natural products not yet approved.
• DMSO compatibility required: Assays must tolerate DMSO at working concentrations; some cell types are sensitive above 0.5–1% final DMSO.
• Mechanism annotation is as per current knowledge: Some compounds may have off-target effects not reflected in the provided documentation.

This article extends the evidence-based focus of "DiscoveryProbe™ FDA-approved Drug Library: Reliable Screening..." by providing atomic, verifiable claims and explicit cross-references to peer-reviewed high-throughput screening benchmarks. For a strategic overview of mechanistic screening, see "Mechanism-Driven Drug Discovery: Strategic Opportunities ...", which this article updates by adding new evidence from viral inhibitor screens.

Workflow Integration & Parameters

APExBIO supplies the DiscoveryProbe™ FDA-approved Drug Library in multiple formats: 96-well shallow and deep well plates, as well as 2D barcoded screw-top tubes. Each compound is a 10 mM solution in DMSO, compatible with automated pipetting systems. The recommended storage is -20°C for up to 12 months or -80°C for up to 24 months. Compounds are shipped on blue ice (evaluation samples) or at room temperature/blue ice (bulk orders), with full documentation for traceability (DiscoveryProbe™ FDA-approved Drug Library).

• Assay setup: Dilute compounds to working concentrations, ensuring DMSO does not exceed cell- or assay-specific maximums (often ≤0.5%).
• Controls: Include DMSO-only negative controls and, where possible, positive control compounds for each target class.
• Readouts: Compatible with cell viability, pathway reporter, cytotoxicity, and biochemical enzyme activity assays.
• Data analysis: Normalize data to controls; Z-factor >0.4 is recommended for HTS quality (per Tseligka et al., 2023).

Detailed workflow scenarios and practical troubleshooting are covered in "DiscoveryProbe™ FDA-approved Drug Library: Reliable Screening...", which this article supplements with new stability and mechanistic data.

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library, curated and supplied by APExBIO, is a cornerstone resource for high-throughput and high-content drug screening. Its rigorously validated compound collection accelerates drug repositioning, target identification, and mechanistic discovery in translational research. Recent peer-reviewed studies confirm its utility in antiviral discovery and beyond. The library's robust documentation, flexible formats, and stability profile position it as a critical tool for biomedical innovation. Ongoing updates to compound annotation and regulatory coverage will further enhance its value for academic and industrial researchers (Tseligka et al., 2023).